- Home
- MPB vs GOSS Comparison
MPB vs GOSS Comparison
Compare MPB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- GOSS
- Stock Information
- Founded
- MPB 1868
- GOSS 2015
- Country
- MPB United States
- GOSS United States
- Employees
- MPB N/A
- GOSS N/A
- Industry
- MPB Major Banks
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- GOSS Health Care
- Exchange
- MPB Nasdaq
- GOSS Nasdaq
- Market Cap
- MPB 695.0M
- GOSS 586.6M
- IPO Year
- MPB N/A
- GOSS 2019
- Fundamental
- Price
- MPB $30.35
- GOSS $2.66
- Analyst Decision
- MPB Buy
- GOSS Strong Buy
- Analyst Count
- MPB 2
- GOSS 4
- Target Price
- MPB $34.50
- GOSS $8.50
- AVG Volume (30 Days)
- MPB 78.4K
- GOSS 3.4M
- Earning Date
- MPB 10-22-2025
- GOSS 11-06-2025
- Dividend Yield
- MPB 2.64%
- GOSS N/A
- EPS Growth
- MPB N/A
- GOSS N/A
- EPS
- MPB 2.30
- GOSS N/A
- Revenue
- MPB $191,454,000.00
- GOSS $40,237,000.00
- Revenue This Year
- MPB $24.57
- GOSS N/A
- Revenue Next Year
- MPB $12.23
- GOSS $30.65
- P/E Ratio
- MPB $13.19
- GOSS N/A
- Revenue Growth
- MPB 13.34
- GOSS N/A
- 52 Week Low
- MPB $22.50
- GOSS $0.66
- 52 Week High
- MPB $33.87
- GOSS $3.00
- Technical
- Relative Strength Index (RSI)
- MPB 66.49
- GOSS 63.57
- Support Level
- MPB $28.08
- GOSS $2.41
- Resistance Level
- MPB $30.73
- GOSS $2.71
- Average True Range (ATR)
- MPB 0.64
- GOSS 0.21
- MACD
- MPB 0.09
- GOSS 0.03
- Stochastic Oscillator
- MPB 85.66
- GOSS 69.77
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.